Biogen's Alzheimer therapy, Leqembi, is gaining traction with Q1'24 sales of $19m, nearly tripling Q4 revenues. Read my ...

Shares of the biopharmaceutical company Biogen (BIIB) are on the rise Wednesday, buoyed by the company's first quarter ...

Biogen is addressing profitability concerns and a lack of top-line growth. Read more to see an overview and analysis of BIIB ...

BIIB stock results show that Biogen beat analyst estimates for earnings per share but missed on revenue for the first quarter ...

It was a busy week in the biotech sector with earnings reports from bigwigs Biogen BIIB and Bristol Myers Squibb BMY. Other regulatory and acquisition updates were in focus as well.

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the June 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

On April 22, 2024, Biogen Inc. (NASDAQ:BIIB) stock closed at $194.11 per share. One-month return of Biogen Inc. (NASDAQ:BIIB) was -10.42%, and its shares lost 33.76% of their value over the last ...

Viehbacher's pay that year was exceeded only by Jason Robins, the CEO of DraftKings, and Douglas Ingram, president and chief ...

It was a busy week in the biotech sector with earnings reports from bigwigs Biogen BIIB and Bristol Myers Squibb ... range of $15.00-$16.00. The Biogen stock rose following the results, as ...